PERSPECTA

News from every angle

← Back to headlines

Abivax Shares Tumble Over 30% After Drug Trial Update

Shares of French biotech company Abivax plummeted 32% following the release of new data from a trial of its lead drug for bowel disease.

2 Jun, 07:28 — 2 Jun, 07:28
PostShare

Sources

Showing 1 of 1 sources
cnbcMostly Factual76d ago

Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update

Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.

Read full article →

Related Stories

Alphabet Plans Debut Australian Dollar Bond Sale for AI Investment

28m ago

Saudi Arabia Offers Oil Near Oman, Signaling Potential Hormuz Shuttling

37m ago

Poland Temporarily Reduces Fuel VAT, Leading to Price Drop

42m ago

HIVE Digital Stock Jumps on Five-Year Nvidia GPU Deal

44m ago